NRX Pharmaceuticals Inc
NASDAQ:NRXP
Balance Sheet
Balance Sheet Decomposition
NRX Pharmaceuticals Inc
NRX Pharmaceuticals Inc
Balance Sheet
NRX Pharmaceuticals Inc
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
28
|
20
|
5
|
1
|
|
| Cash |
0
|
0
|
0
|
0
|
28
|
20
|
5
|
1
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
5
|
6
|
2
|
2
|
|
| Total Current Assets |
1
|
0
|
0
|
0
|
33
|
26
|
7
|
3
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
69
|
71
|
32
|
6
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
70
N/A
|
71
+2%
|
32
-55%
|
6
-81%
|
33
+441%
|
26
-21%
|
7
-72%
|
4
-50%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
1
|
1
|
1
|
4
|
2
|
5
|
4
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
2
|
5
|
5
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
1
|
8
|
9
|
1
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
6
|
1
|
1
|
14
|
|
| Total Current Liabilities |
0
|
1
|
1
|
1
|
12
|
16
|
19
|
22
|
|
| Long-Term Debt |
0
|
1
|
2
|
3
|
0
|
3
|
0
|
5
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
1
+1 252%
|
3
+105%
|
4
+53%
|
12
+203%
|
18
+54%
|
19
+3%
|
27
+41%
|
|
| Equity | |||||||||
| Common Stock |
64
|
65
|
25
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
0
|
1
|
183
|
223
|
253
|
278
|
|
| Additional Paid In Capital |
5
|
5
|
5
|
3
|
204
|
230
|
241
|
255
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
69
N/A
|
70
+0%
|
30
-58%
|
2
-93%
|
21
+884%
|
7
-64%
|
12
N/A
|
23
-98%
|
|
| Total Liabilities & Equity |
70
N/A
|
71
+2%
|
32
-55%
|
6
-81%
|
33
+441%
|
26
-21%
|
7
-72%
|
4
-50%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
0
|
6
|
7
|
84
|
15
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
|